An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Launched by ABBVIE · Feb 15, 2019
Trial Information
Current as of April 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is an extension study for patients with certain types of cancer, including chronic lymphocytic leukemia and multiple myeloma, who have already been participating in a previous study using the drug venetoclax. The aim of this study is to continue providing venetoclax to these patients in order to gather long-term safety information and to ensure that those who are benefiting from the medication can keep receiving it.
To be eligible for this study, participants must have previously been enrolled in a venetoclax trial and should still be feeling well and gaining benefits from the treatment. Both men and women can participate, but men need to agree not to donate sperm, and women must not be pregnant or breastfeeding. This study is currently active but not recruiting new participants, so it focuses on those who are already involved. Participants can expect to continue their treatment while helping researchers learn more about the long-term effects of venetoclax.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- • Male subject agrees to refrain from sperm donation.
- • Female subjects must not be pregnant or breastfeeding.
- Exclusion Criteria:
- • - None.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tucson, Arizona, United States
Los Angeles, California, United States
Harvey, Illinois, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Lebanon, New Hampshire, United States
Canton, Ohio, United States
Seattle, Washington, United States
Camperdown, New South Wales, Australia
Darlinghurst, New South Wales, Australia
Kogarah, New South Wales, Australia
Liverpool, New South Wales, Australia
Melbourne, Victoria, Australia
Murdoch, Western Australia, Australia
Nedlands, Western Australia, Australia
Graz, Steiermark, Austria
Woluwe Saint Lambert, Bruxelles Capitale, Belgium
Quebec City, Quebec, Canada
Copenhagen ø, Hovedstaden, Denmark
Aarhus N, Midtjylland, Denmark
Pierre Benite Cedex, Auvergne Rhone Alpes, France
Athens, Attiki, Greece
Thessaloniki, , Greece
Hong Kong, , Hong Kong
Beaumont, Dublin, Ireland
Morelia, Michoacan, Mexico
Monterrey, Nuevo Leon, Mexico
Papatoetoe, Auckland, New Zealand
Takapuna, Auckland, New Zealand
Newtown, Wellington, New Zealand
Krakow, Malopolskie, Poland
Warszawa, Mazowieckie, Poland
Chorzow, Slaskie, Poland
Lisboa, , Portugal
Moscow, Moskva, Russian Federation
Penza, Penzenskaya Oblast, Russian Federation
Madrid, , Spain
Lund, Skane Lan, Sweden
Taichung City, , Taiwan
Taipei City, , Taiwan
Ankara, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Izmir, , Turkey
Samsun, , Turkey
Bristol, Bristol, City Of, United Kingdom
Southampton, Hampshire, United Kingdom
Blackpool, , United Kingdom
Liverpool, , United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Wolverhampton, , United Kingdom
Canton, Ohio, United States
Pierre Benite Cedex, Auvergne Rhone Alpes, France
La Tronche, , France
Kobe Shi, Hyogo, Japan
Higashi Ibaraki Gun, Ibaraki, Japan
Okayama Shi, Okayama, Japan
Chuo Ku, Tokyo, Japan
Seoul, , Korea, Republic Of
Dnipro, , Ukraine
Leicester, England, United Kingdom
London, , United Kingdom
London, , United Kingdom
Seattle, Washington, United States
Graz, Steiermark, Austria
Pierre Benite Cedex, Rhone, France
Papatoetoe, Auckland, New Zealand
Krakow, Malopolskie, Poland
Taichung, , Taiwan
Graz, Steiermark, Austria
Woluwe Saint Lambert, Bruxelles Capitale, Belgium
Aarhus, Midtjylland, Denmark
La Tronche, Isere, France
Dublin, , Ireland
Krakow, Malopolskie, Poland
Lund, Skane Lan, Sweden
Taipei City, Taipei, Taiwan
Plymouth, Devon, United Kingdom
Liverpool, , United Kingdom
Lebanon, New Hampshire, United States
Seattle, Washington, United States
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
London, Greater London, United Kingdom
Higashi Ibaraki Gun, Ibaraki, Japan
Bruxelles, Bruxelles Capitale, Belgium
London, Greater London, United Kingdom
London, Greater London, United Kingdom
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials